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Introduction: Transforming growth factor-βs (TGF-βs) play a dual role in breast cancer, with context-dependent
tumor-suppressive or pro-oncogenic effects. TGF-β antagonists are showing promise in early-phase clinical oncology
trials to neutralize the pro-oncogenic effects. However, there is currently no way to determine whether the
tumor-suppressive effects of TGF-β are still active in human breast tumors at the time of surgery and treatment, a
situation that could lead to adverse therapeutic responses.
Methods: Using a breast cancer progression model that exemplifies the dual role of TGF-β, promoter-wide chromatin
immunoprecipitation and transcriptomic approaches were applied to identify a core set of TGF-β-regulated genes that
specifically reflect only the tumor-suppressor arm of the pathway. The clinical significance of this signature and the
underlying biology were investigated using bioinformatic analyses in clinical breast cancer datasets, and knockdown
validation approaches in tumor xenografts.
Results: TGF-β-driven tumor suppression was highly dependent on Smad3, and Smad3 target genes that were
specifically enriched for involvement in tumor suppression were identified. Patterns of Smad3 binding reflected
the preexisting active chromatin landscape, and target genes were frequently regulated in opposite directions in vitro
and in vivo, highlighting the strong contextuality of TGF-β action. An in vivo-weighted TGF-β/Smad3 tumor-suppressor
signature was associated with good outcome in estrogen receptor-positive breast cancer cohorts. TGF-β/Smad3 effects
on cell proliferation, differentiation and ephrin signaling contributed to the observed tumor suppression.
Conclusions: Tumor-suppressive effects of TGF-β persist in some breast cancer patients at the time of surgery and
affect clinical outcome. Carefully tailored in vitro/in vivo genomic approaches can identify such patients for exclusion
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Gene expression profiling approaches have highlighted the
molecular heterogeneity of breast cancer [1], and identi-
fied gene expression fingerprints of molecular pathway
activation [2]. A greater understanding of the contribution
of different signaling pathways will be critical for the
development of precision medicine approaches to cancer
therapy. Transforming growth factor-βs (TGF-βs) are
highly pleiotropic regulatory proteins that play complex
roles in epithelial carcinogenesis, and the prevailing
dogma is that they switch from a predominantly tumor-
suppressive role to a tumor-promoting role as disease
progresses (reviewed in [3-5]). Based on encouraging
preclinical data showing that the deleterious pro-
oncogenic arm of the TGF-β biological response program
can be effectively blockaded for therapeutic benefit,
TGF-β antagonists are now in early phase clinical trials
in oncology in several tumor types [6], including breast
cancer (http://clinicaltrials.gov Trial NCT01401062). How-
ever, the specter remains that such interventions could
inadvertently interfere with residual tumor suppressive
activity and thus adversely affect outcome. Here we have
asked if genomic approaches can be used to discern
whether tumor-suppressive effects of TGF-β do indeed
persist and influence survival in any human breast cancers
at the time of surgery.
Mechanisms underlying the dual role model for TGF-
β in cancer progression involve a wide variety of TGF-β
effects on both the tumor parenchyma and the support-
ing stromal microenvironment. Tumor-suppressive effects
include the induction of various protective responses to
counteract genetic damage and oncogene activation [7-10],
as well as the maintenance of a tumor-suppressive cytokine
and chemokine profile in the microenvironment [11-13].
However as disease progresses, activation of oncogenic
pathways in the tumor parenchyma can not only override
the tumor-suppressive responses to TGF-β, but can also
unmask pro-progression responses such as induction of
the epithelial-to-mesenchymal transition, enhanced
migration and invasion, and expansion of the cancer
stem cell compartment [14-18]. At the same time, the
excessive TGF-β that is frequently found in the micro-
environment of advanced tumors can subvert antitumor
immune surveillance, promote angiogenesis, and gener-
ally contribute to the development of a more supportive
tumor stroma [19-21].
Preclinical studies in model systems have provided
considerable support for a dual role for TGF-β in breast
cancer (reviewed in [22,23]). TGF-β was shown to switch
from tumor-suppressor to prometastatic factor with dis-
ease progression in both a HER2/Neu-driven genetically
engineered mouse model and a Ras-driven human xeno-
graft model of breast cancer [24,25]. In contrast, studies
in the MMTV-PyVT mouse model of breast cancer havesuggested that tumor-suppressive effects of the TGF-β
pathway may persist even in late-stage metastatic disease
[26-28]. Currently, the relative importance of the two
different aspects of TGF-β biology in determining
clinical outcome in human breast cancer patients is not
clear. TGF-β pathway components are rarely mutated or
deleted in breast cancer [29], so the effects of any TGF-
β pathway perturbation in the clinical situation are likely
to be more subtle than is seen with preclinical knockout
models. Interestingly, the majority of human breast can-
cer cell lines have lost their growth inhibitory responses
to TGF-β in vitro [30], and only MCF10Ca1h cells have
been definitively shown to retain tumor-suppressive
responses to endogenous TGF-β in vivo [25]. This situ-
ation could reflect an early loss of TGF-β-driven tumor
suppression in the majority of human breast cancers. In-
deed, reduced expression of the type II TGF-β receptor
has been seen in epithelial hyperplasia without atypia,
the very earliest preneoplastic lesion of the breast [31].
Alternatively, it may simply reflect challenges in estab-
lishing cell lines from breast cancers that retain such
responses.
The possible persistence of tumor-suppressive effects
of TGF-β in human breast cancers at the time of clinical
intervention has profoundly important implications for
the deployment of TGF-β-targeted therapies. To address
this question rigorously, we chose to develop a gene
signature for TGF-β-driven tumor suppression. Several
TGF-β-related gene expression signatures have been de-
veloped previously [2,11,18,32-36], but they were not de-
signed a priori to discriminate between tumor-suppressive
and pro-progression responses to TGF-β. Furthermore,
such signatures are almost invariably associated with poor
prognosis, suggesting that the pro-oncogenic activities of
the TGF-β pathway are more readily captured by these ap-
proaches than are the tumor-suppressive activities. Here
we describe an integrated in vitro/in vivo genomic strategy
to identify a gene signature that specifically reflects TGF-
β-driven tumor-suppressive effects on the tumor paren-
chyma. We show that high expression of the signature
predicts good outcome in clinical datasets from estrogen
receptor-positive (ER+) breast cancer patients, a finding
that suggests there is a subset of such patients who should
not be treated with TGF-β pathway antagonists. Our
approach also revealed novel aspects of TGF-β biology,
highlighting effects of TGF-β on breast cancer differenti-
ation and linking ephrin signaling to TGF-β-mediated
tumor suppression.
Methods
Cell lines and reagents
The MCF10A-derived cell lines [37,38] were obtained
from the Barbara Ann Karmanos Cancer Institute Cell
Line Resource, (Detroit, MI, USA) and were cultured as
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taneously immortalized human breast epithelial cells de-
rived from a woman with fibrocystic breast disease [39].
MCF10AT1k.cl2 (‘M2’) was derived from MCF10A by
transfection with mutant Ha-Ras followed by in vivo
selection for cells that gave rise to preneoplastic lesions
and subsequent in vitro cloning from the lesions.
MCF10Ca1h (‘M3’) and MCF10Ca1a.cl1 (‘M4’) were cul-
tured from rare tumors that arose from the premalignant
MCF10AT1k.cl2 cells following implantation in vivo
[37,38]. Although the MCF10A parental cell line is ER-
negative, the derivative Ras-transformed cell lines show
varying degrees of ER positivity and biological responses
to estrogen in vitro and in vivo [40-43]. In particular, we
and others have shown that tumors derived from M3 cells
contain ER+ cells in the differentiated regions ([38] and
Additional file 1) and thus model ER+ breast cancer. They
are genetically wild type for p53 but have mutated
PIK3CA [44], which are also characteristics of human
ER+ breast cancers [45,46]. Smad2 and Smad3 null condi-
tionally immortalized mouse mammary epithelial cells
(IMECs) were generated and cultured as described previ-
ously [47]. For all in vitro assays, cells were grown to
50 to 60% confluence and then serum-starved in DMEM/
F12 supplemented with Serum Replacement 1 (Sigma-
Aldrich, St. Louis, MO, USA) for 16 hours prior to TGF-β
treatment. Recombinant human EphrinA1-Fc chimera
was purchased from R&D Systems Inc. (Minneapolis,
MN, USA).
ShRNA knockdown and gene overexpression
For gene knockdown experiments, short hairpin RNA
(shRNA) against target sequences in SMAD2 (5′-GCAC
TTGCTCTGAAATTTG-3′) and SMAD3 (5′-GGCCAT
CACCACGCAG AAC-3′), were cloned into the pLKO.1
lentiviral vector. shRNA against GFP RNA (5′-AAGAC
CCGCGCCGAGGTGAAG-3′) was used as a control.
EFNA1 shRNA lentiviral constructs (TRCN0000007311
in pLKO.1; V3LHS_360202, V3LHS_360203 in pGIPZ)
were purchased from Open Biosystems Inc., (Huntsville,
AL, USA). A dominant negative human type II TGF-β
receptor (dnTβRII) consisting of amino acids 1-219 of
TGFBR2 coupled to a Myc or V5 tag was cloned into
pLPCX retroviral (BD Biosciences Clontech, Palo Alto,
CA, USA) or pLenti6.2/V5-DEST Gateway lentiviral
(Invitrogen, Carlsbad, CA, USA) backbones respectively.
Lentiviral constructs were transfected into the 293FT
producer cell line using the pPACKH1 lentivector pack-
aging kit (System Biosciences, Mountain View, CA,
USA) and Lipofectamine 2000 (Invitrogen). Pseudoviral
particles were isolated by centrifugation and incubated
with M3 and M4 cells for 24 hours. The cells were
grown for an additional 48 hours after transduction and
then maintained under puromycin selection (4 μg/ml)for five days. In vivo experiments were performed within
three to five passages after transduction using pools of
transduced cells. Knockdown or overexpression were con-
firmed by RT-QPCR and Western blot analysis. Activity of
the dnTβRII was confirmed by the ability to block TGF-β-
inducible Smad2 phosphorylation and TGF-β-inducible
activity of the Smad3 reporter CAGA12-luciferase, follow-
ing transient transfection with pGL3(CAGA12)-Luc.
Western blotting
Whole-cell extracts were prepared in M-PER (Thermo
Fisher Scientific Inc., Pittsburgh, PA, USA) containing
Complete Protease Inhibitor cocktail (Roche Applied
Science, Indianapolis, IN, USA) and phenylmethylsulfo-
nyl fluoride (Sigma-Aldrich). Typically, 35 μg of total
protein was loaded on to 4 to 20% Tris-Glycine SDS-
PAGE gels (Invitrogen) and transferred to PVDF mem-
brane (Millipore, Temecula, CA, USA). Antibodies were as
follows: Smad3 antibody (Ab28379, ChIP grade, Abcam,
Cambridge, MA, USA), Smad2 antibody (15-1300, Invi-
trogen), anti-Smad3 phosphoS423/425 antibody (Smad3-
CP, 1880-1, Epitomics, Burlingame, CA, USA), anti-linker
phospho S208 Smad3 antibody (Smad3-LP) was gener-
ously provided by Dr. Fang Liu (Rutgers University, NJ,
USA), anti-Ephrin-A1 antibody (3880-1, Epitomics or
SC-911, Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA), anti-Eck/EphA2, clone7 (05-480, Millipore),
anti-phosphoEphA2-S897 (035118, US Biological, Salem,
MA, USA). Anti-β-actin (A-2228, Sigma-Aldrich) was
used to assess equivalence of protein loading. Peroxidase-
conjugated secondary antibodies were used at 1:5000
dilution and the signals were detected by ECL (Thermo
Scientific Pierce, Rockford, IL, USA). Scanned Western
blots were quantitated using MultiGauge Analysis Soft-
ware (Fujifilm, Tokyo, Japan).
Chromatin immunoprecipitation (ChIP) and methylated
DNA immunoprecipitation (MeDIP)
Cells were grown to 50 to 60% confluence in complete
medium and then switched to DMEM/F12 medium con-
taining Serum Replacement 1 (Sigma-Aldrich) at a final
concentration of 1x for 16 hours before treatment with
5 ng/ml of TGF-β1 or vehicle for 1 hour. 1 × 108 cells
from vehicle or TGF-β-treated cultures were washed
once with PBS and then dual cross-linked at room
temperature successively with 2 mM di-(N-succinimi-
dyl) glutarate (DSG, Thermo Scientific) for 30 minutes
and 1% formaldehyde for 10 minutes. We found the
DSG cross-linking step significantly increased the re-
covery of TGF-β-induced Smad3-bound DNA when
compared with formaldehyde fixation alone. Glycine
was added to a final concentration of 0.25 M to stop the
fixation. Cells were washed twice with ice-cold PBS,
scraped, snap-frozen in liquid nitrogen and stored at -80C
Sato et al. Breast Cancer Research 2014, 16:R57 Page 4 of 23
http://breast-cancer-research.com/content/16/3/R57until further processing. For Smad3 ChIP, cells were resus-
pended and sonicated in 3 ml of SDS lysis buffer (1% SDS,
10 mM EDTA, 50 mM Tris-HCl, pH 8.0) to a fragment
size of 200 to 500 bp on ice using a Misonix™ sonicator
with the following pulse parameters: time on = 15 seconds,
time off = 10 seconds, total sonication time for 10 minutes
at power level = 3 to 4. The lysates were centrifuged at
15,000 × g for 10 minutes and diluted 10-fold with ChIP
dilution buffer (0.01% SDS, 16.7 mM Tris-HCl, pH 8.0,
1.2 mM EDTA, 1.1% Triton™ X-100, 167 mM NaCl) and
precleared with Dynabead™ Protein A (Invitrogen) for 30
minutes, followed by incubation with 3 μg/ml anti-Smad3
antibody (# 28379, ChIP grade, Abcam) or rabbit im-
munoglobulin G (IgG) for overnight at 4°C. Protein A
beads were added and incubated for 1 hour at 4°C, and
beads were then washed successively with low (0.1%
SDS, 20 mM Tris-HCl, pH 8.0, 2 mM EDTA, 1% Triton™
X-100, 150 mM NaCl) and high (0.1% SDS, 20 mM
Tris-HCl, pH 8.0, 2 mM EDTA, 1% Triton™ X-100, 500 mM
NaCl) salt washing buffer, LiCl wash buffer (10 mM
Tris-HCl, pH 8.0, 1 mM EDTA, 1% NP-40, 1% deoxy-
cholic acid sodium salt, 0.25 M LiCl) and TE buffer.
ChIPed DNA was eluted in SDS elution buffer at room
temperature (RT) with occasional vortexing and the
cross-linking was reversed by overnight incubation at
65°C.
Smad3 ChIPed DNA was amplified using Whole
Genome Amplification and Reamplification kits (Sigma-
Aldrich). ChIP-QPCR for known Smad3 target genes
(JUNB, SERPINE1, SMAD7) confirmed successful amp-
lification. Amplified ChIPed DNA was biotinylated ac-
cording to the standard Affymetrix protocol (Affymetrix
Chromatin Immunoprecipitation Assay Protocol). Follow-
ing fragmentation, 10 μg of biotinylated DNA was hybrid-
ized for 16 hours at 45°C to an Affymetrix promoter tiling
array (GeneChip™ Human Promoter 1.0R Array; 25,500
promoters, 25-mer probes, Affymetrix, Santa Clara, CA,
USA) according to the manufacturer’s instructions. Gene-
chips™ were washed and stained in the Affymetrix Fluidics
Station 450, and then scanned using an Affymetrix Gene-
Chip™ Scanner 3000 7G. Data was collected using Affyme-
trix AGCC software. Each ChIP experiment was conducted
in quadruplicate (M1 cells and M2 cells) or duplicate (M3
cells and M4 cells) for independent chromatin isolations.
Histone H3 with acetylation on lysine residues 9/14
(H3AcK9/14) has previously been shown to be highly lo-
calized to the 5′ regions of transcriptionally active hu-
man genes [48] or genes that are poised for transcription
[49]. To determine the chromatin activation state of se-
lect Smad3 binding regions, ChIP analysis for acetylated
histones in untreated M1 to M4 cells grown in complete
medium was carried out as previously described [50],
using a ChIP assay kit (Upstate, Temecula, CA, USA),
with antibodies against H3AcK9/14 (antibody #06-599,Upstate). QPCR was performed to determine enrich-
ment of target genomic regions in the immunoprecipi-
tated fraction compared with input DNA. Similarly, to
assess the methylation status of DNA targets, immuno-
precipitation of methylated DNA (MeDIP) was per-
formed. 1 μg whole DNA from all four cell lines (M1 to
M4 untreated, complete medium) was sonicated in TE
buffer (Sonicator, Misonix Inc., NY, USA; setting: power
3, 30 seconds ON, 20 seconds OFF, four times on ice).
DNA samples were denatured at 99°C for 5 minutes then
snap-cooled in iced water. Anti-5-methyl cytosine poly-
clonal antibody (CP51000, rabbit, Megabase Research
Products, Lincoln, NE, USA) was incubated with the soni-
cated DNA for 2 hours at 4°C, followed by incubation
with Dynabead Protein A (Invitrogen) for 1 hour. Super-
natant was collected as unbound fraction, and beads
were then washed three times with MeDIP washing
buffer (10 mM Tris-HCl, 150 mM NaCl, 0.05% Triton
X-100 and 0.01% BSA) and once with TE buffer. Immu-
noprecipitated DNA was eluted in SDS elution buffer
(1% SDS, 10 mM Tris-HCl, pH 8.0, 5 mM EDTA, 300
mM NaCl), at RT for 10 minutes, and then incubated at
55°C for 3 hours with proteinase K. DNA was extracted
using Qiagen Enzymatic reaction clean-up kit (Qiagen,
Germantown, MD, USA) to give the MeDIP fraction.
QPCR analysis was performed to determine enrichment
of genomic regions in MeDIP fractions, normalized to
unbound DNA.
ChIP-QPCR and MeDIP QPCR
Smad3 occupancy at previously known targets as well
as at select target genes identified by ChIP-chip was
validated by QPCR of Smad3 ChIPed DNA following
whole genome amplification, using Power SYBR Green
PCR master mix (Applied Biosystems, Carlsbad, CA,
USA) with ABI-PRISM 7900 Sequence Detection Sys-
tem (Applied Biosystems). The enrichment of ChIP
DNA was calculated relative to the input DNA using
gene-specific primer sets to the Smad binding region
(SBRs) identified from the ChIP-chip analysis, and was
compared with ChIP for control IgG. Similarly, QPCR of
MeDIP DNA and of DNA ChIPed for histone H3AcK9/14
was performed for select SBRs. PPIA was used as a nega-
tive control for Smad3 ChIP and MeDIP and a positive
control for H3AcK9/14 ChIP. Conversely, MyoD served
as a positive control for MeDIP and a negative control for
H3AcK9/14 ChIP. The primer pairs used for QPCR are
given in Additional file 2.
Smad3 ChIP-chip data analysis
Affymetrix Tiling Analysis Software (TAS, version 1.2.0)
was used for data processing. Quantile normalization
was performed within each comparison group; quadru-
plicate for M1 and M2 cells and duplicate for M3 and
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window size of 200 bp (bandwidth = 100 bp), and a
minimum run of 200 bases with a maximum gap of 100
bases. Relative enrichment of TGF-β-dependent Smad3
binding was estimated from the signal difference be-
tween vehicle-treated and TGF-β-treated samples with a
false discovery rate (FDR) of 15%. The analyzed data was
visualized using Integrated Genome Brower [51] for each
cell line. Enriched regions that overlapped with or were
within 10 kb upstream or downstream of known pro-
moter regions (Affymetrix Hs_PromP_NCBlv36.acces-
sion) were retained. Galaxy web server [52] and UCSC
Genome Browser tables (‘hg18.knownGene’) were used
to annotate enriched regions with target transcripts of
known genes. Genes were assigned to bound genomic
regions based on the gene transcription start site (TSS)
distance to the midpoint of the Smad3 binding region
(SBR). Both multiple target transcripts and the gene with
the shortest TSS distance to the region midpoint were
analyzed. On average, 72% of all enriched regions for
each of the four cell lines were annotated with known
genes.
To generate a probability density plot for the occur-
rence of SBRs in relation to the closest TSS, binding
sites within the −7.5 kb to +2.5 kb genomic region for
the target genes were used. Data for each cell line was
analyzed independently. The distributions were obtained
using kernel density estimates [53] implemented in R
[54]. To determine the distribution of SMAD binding
sites within the SBRs, a set of high confidence positive
peaks identified in both M3 and M4 cells was used. After
merging overlapping peaks, the final set had 190 regions.
Sequences consisting of peak midpoints +/−1000 bp were
divided in 100 bp bins. The bins of each peak were scored
for the presence of one or more SMAD binding site. Data
for bins equidistant from the midpoint (for example 100
bp upstream and 100 bp downstream) were combined.
The fraction of bins with SMAD sites was compared at
equivalent bin positions for the 190 SBRs and 190 ran-
domly selected promoter regions that did not show
Smad3 binding. Two-way ANOVA was performed to ask
whether the fraction of peaks with a SMAD site differed
significantly with respect to group (positive vs. negative
peaks) and distance from peak midpoint.
To identify enriched transcription factor (TF) binding
sites within the SBRs, the set of 190 binding regions iden-
tified above was used. The midpoint of each peak was de-
termined, and chromosome sequences consisting of the
midpoint nucleotide flanked by 250 bp were examined for
the presence of transcription factor binding sites. If neces-
sary, boundaries of regions were adjusted to eliminate
overlaps between adjacent sequences. Transcription factor
binding sites were identified using the Genomatix soft-
ware suite [55]. Overrepresented TF binding sites withinpeaks were identified using the RegionMiner tool. Co-
occurrence of TF sites was determined within peak
midpoint +/−250 bp regions for SMAD and the six
additional most highly overrepresented TF matrices in
the 190 binding regions. MatInspector was used to
identify TF binding sites in each binding region. Redun-
dant TF sites were removed (for example a generic
SMAD site and a SMAD3 site mapped to the same lo-
cation were counted as one site) and multiple motifs
for each TF were collapsed down to a single motif (for
example AP1.01 and AP1.02 were reduced to AP1). For
each pair of TF factors, the number of peak sequences
that contained both sites was determined. P values for
co-occurrence were calculated using Fisher’s exact test,
where TF site co-occurrence in positive peaks were com-
pared to co-occurrence in the set of 190 control promoter
regions which showed no Smad3 binding. P values were
adjusted for multiple comparisons using the Bonferroni
correction.
Global gene expression analysis
In parallel with the Smad3 ChIP-chip analysis, M1 to
M4 cells were treated in vitro with TGF-β for 1 hour
and 6 hours and RNA was isolated for gene expression
analysis using RNeasy™ kit (Qiagen). RNA quality was
checked on Agilent Bioanalyzer 2100 (Agilent Technolo-
gies, Santa Clara, CA, USA). All samples used for micro-
array analysis have high quality score (RIN >9). A total
of 100 ng of RNA was reverse transcribed and amplified
using an Ambion WT expression kit following the man-
ufacturer’s instructions. Sense strand cDNA was frag-
mented and biotinylated using Affymetrix WT Terminal
Labeling Kit. Three biological replicates for each con-
dition were hybridized to the Affymetrix GeneChip™
Human ST1.0 in a hybridization oven at 45°C, 60 rpm
for 16 hours. Washing and staining were performed on an
Affymetrix Fluidics Station 450 using the Affymetrix Gene-
Chip™ Hybridization Wash and Stain Kit containing R-
phycoerythrin, strepavidin and biotinylated anti-streptavidin
antibody, and Genechips were then scanned on an Affyme-
trix GeneChip™ scanner 3000 7G. Data was collected using
Affymetrix AGCC software. To assess the regulation of tar-
get genes by TGF-β in M3 cells in vivo, gene expression
arrays were also performed for tumor xenografts of M3
cells transduced with pLPCX retrovirus with no insert
(M3-CON) or pLPCX expressing a dominant negative
type II TGF-β receptor (M3-dnTβRII). Six tumors were
arrayed for each genotype group. All expression arrays
were normalized by the RMA method using the
Affymetrix Expression Console.
RT-QPCR
RNA prepared by the RNeasy method (Qiagen) from M3
tumors transduced with lentiviruses expressing shGFP
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also analyzed by RT-QPCR. cDNA was synthesized using
Superscript III (Invitrogen) and RT-QPCR was performed
using Power SBYR Green PCR Master Mix (Applied Bio-
systems) and an ABI PRISM™ 7900 HT Sequence Detection
System (Applied Biosystems). Three biological replicates of
each tumor type or each in vitro cell treatment condition
were used for all RT-QPCR validation experiments. Expres-
sion was normalized to PPIA and fold change in expression
was calculated relative to the indicated conditions. Primer
pairs used for RT-QPCR are given in Additional file 3.
Integration of ChIP-chip and gene expression array
datasets and signature generation
To identify the TGF-β/Smad3-dependent gene expres-
sion signature, Smad3 ChIP-chip data and microarray-
based gene expression datasets were integrated using
Partek Genomic Suite 6.5 (Partek, St. Louis, MO, USA).
Gene expression datasets were log2 transformed and quan-
tile normalized. ANOVA analysis was then performed on
the set of Smad3 target genes that had been identified by
ChIP-chip, to select for TGF-β/Smad3 target genes that
were differentially expressed, based on FDR <0.05, across
the four target conditions in vitro (M3 cells −/+TGF-β and
M4 cells −/+TGF-β). Unsupervised hierarchical cluster
analysis was performed, in which genes showing the most
variation in expression across the four treatment groups as
determined above were computed using Euclidean distance
metric and average linkage clustering for both ‘genes’ and
‘groups’ and then used to generate heat maps. Smad3 target
genes that showed significant regulation by TGF-β treat-
ment in vitro were then assessed for regulation in vivo by
comparing gene expression array datasets generated from
M3-CON and M3-dnTβRII tumors (six tumors/genotype
group) on the Affymetrix Human 1.0ST array platform.
An FDR cutoff of 0.2 was used to identify differentially
expressed genes in the in vivo datasets. Despite the low
stringency cutoff, all 26 genes identified by microarray
as being uniquely regulated by TGF-β in M3 cells
in vitro and also regulated by TGF-β in M3 tumors
in vivo were validated by RT-QPCR (see Results).
Meta-analysis of gene expression in clinical breast cancer
datasets
Meta-analysis of the association of individual genes or
the gene expression signatures with clinical parameters
and outcome in human breast cancer array datasets was
performed using the GSA tumors function in the online
tool GOBO (gene expression-based outcome for breast
cancer online) [56,57]. The tumor dataset used for the
GOBO analyses consists of a total 1,881 samples, with
the following characteristics: 1,225 ER+ tumors, 395 ER-
tumors, 927 tumors from patients who received no sys-
temic therapy (untreated) and 326 tamoxifen-treatedtumors. All tumors were arrayed on the Affymetrix
U133A array and came from 11 independent datasets. Im-
portantly, the GOBO analysis tool allows for directional
weighting (positive or negative) of component genes of a
signature. Thus genes that were upregulated by TGF-β
were assigned a weight of +1, and genes that were down-
regulated were assigned a weight of −1. Depending on the
analysis, we used the directional weightings that we deter-
mined in vitro or in vivo, as indicated in the text. For gene
sets such as the TGF-β/Smad3 tumor-suppressor signa-
ture (TSTSS), the program computes an averaged gene set
expression, including weights, prior to dividing the entire
dataset into patient cohorts based on gene expression
quantiles. In our analyses, datasets were dichotomized to
high (above median) and low (below median) expression
values for the gene or gene set in question, and Kaplan-
Meier analysis was performed to determine association of
gene expression with outcome. Multivariate analyses, and
analyses of gene expression patterns across clinical groups
were also performed with the GOBO tool.
To assess the performance of the TSTSS in independent
breast cancer gene expression datasets obtained using
different microarray platforms, the Nederlands Kanker
Instituut (NKI) dataset using a custom spotted cDNA
array [58], and the Cancer Genome Atlas (TCGA) data-
set [59] using a Illumina microarray platform were used
(Illumina Inc., San Diego, CA, USA). The NKI dataset
has 337 samples (249 ER+ and 88 ER- tumors) and 19
out of the 26 genes of the TSTSS were found in this
dataset, while the TCGA dataset has 525 breast tumors
(407 ER+ and 118 ER-) and 24 of the 26 TSTSS genes
were found. We applied the R package ‘survival’ [54] to
estimate the probability of distant metastasis-free sur-
vival and overall survival in these datasets using the
Kaplan-Meier method. For each sample, we computed
the weighted sum of expression of the genes of the
TSTSS. From these sums, we defined a factor variable
with value High if the sum was greater than the median
of the sums, and Low if the sum was not greater than
the median. The factor variable and the log rank test
were used to test the difference between the two
groups. The analysis was applied to all samples, and to
ER+ and ER- subgroups. To assess the validity of the
signature, permutation analysis was performed for the
weight vectors and genes of the TSTSS within the data-
set GSE6532. In this dataset, expression data were
found for 22 out of the 26 genes. The number of all pos-
sible (−1 or 1) binary vectors is 4194304. The Kaplan-Meier
analyses of the signatures using all possible weight vectors
showed that the in vivo TSTSS combination outperformed
97% of all possible combinations. We also tested 10,000
random subsets of the 22 genes with random binary vectors
to combine them. The in vivo TSTSS combination outper-
formed 98% of the 10,000 random subset signatures.
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A published metaPCNA index [60] was used as a surro-
gate for cellular proliferation in the gene expression
datasets. The metaPCNA index is the median expression
of the top 1% of genes that were most highly positively
correlated with the proliferation marker proliferating cell
nuclear antigen (PCNA) in the GSE2361 dataset, which
represents gene expression profiles from 36 different
normal human tissues [61]. We similarly generated a
metaEphrin index that consisted of the weighted sum of
the top 30 genes most highly positively correlated with
EFNA1 in the GSE2361 dataset, using the correlation
coefficients as weights. We also generated a metaDiff
index, representing luminal differentiation, that is the
median expression of a manually curated list of 11 genes
that were highly expressed in differentiated luminal or lu-
minal progenitor cells of the normal breast epithelium in
multiple studies [62-64]. The genes of the metaDiff index
were: FOXA1, CITED1, GATA3, ESR1, PGR, WNT4,
KRT19, MUC1, ELF5, KIT, CYP24A1. The Spearman cor-
relation was performed to determine the relationship be-
tween the TSTSS and the various indices in individual
datasets after the removal of outliers. Outliers were de-
fined as follows: Given a data vector x, let q1 and q3 be
the 1st and 3rd quartiles of x, that is, q1 =Q(0.25) the 25%
quantile and q3 =Q(0.75) the 75% quantile. Define inter-
quartile range (IQR) = q3-q1. Let m be the median of x.
Define the interval [a,b] = [m-1.5*IQR, m + 1.5*IQR]. Any
data outside this interval are outliers. By this definition,
fewer than six points were dropped from any given data-
set. The metaPCNA index was also used as a proliferation
surrogate in multivariate analysis of the prognostic power
of the TSTSS in the breast cancer datasets.
Tumorigenesis
For tumorigenesis assays, M3 or M4 cells were suspended
in serum-free DMEM/F12 medium, and 5 × 105 cells were
injected into the #2 and #7 mammary fat pads of six- to
eight-week-old female athymic NCr nu/nu mice. Tumors
were measured weekly with calipers and all mice on a
given experiment were euthanized with CO2 when the
first tumor in any experimental group reached 2 cm in
diameter. All animal studies were done under a protocol
(LC-070) approved by the National Cancer Institute, in ac-
cordance with Association for Assessment and Accredit-
ation of Laboratory Animal Care (AAALAC) Guidelines
and policies established by the NIH.
Immunohistochemistry and histopathology
Formalin-fixed, paraffin-embedded tumor xenografts were
immunostained with antibodies against cytokeratin 8 (CK8;
Troma-1, Hybridoma Bank, Iowa, IA, USA), estrogen
receptor α (ER-α; MC-20, sc-542, Santa Cruz Biotechnol-
ogy Inc.), angiopoietin-like 4 (#18374, Proteintech Group,Chicago, IL, USA) and serpinE1 (AF1786, R&D Systems).
Immune complexes were detected using the Vectastain
Elite ABC Peroxidase Kit (Vector Labs, Burlingame,
CA, USA) and the two-component DAB substrate pack
(Biogenex, San Ramon, CA, USA), as directed by the
manufacturers. The primary antibody was omitted as a
negative control. Images were captured using an Axioplan
Universal microscope (Zeiss, Oberkochen, Germany), and
immunostaining in five to ten randomly selected high
power fields (CK8: 20X objective; ER: 40X objective) was
quantitated using ImagePro Plus Software (MediaCyber-
netics Inc., Silver Spring, MD, USA). To determine the
extent of histological differentiation of the tumors, the
tumor area occupied by well-differentiated glandular-
like structures was assessed by a pathologist as previ-
ously described [65].
Accession numbers
The ChIP-chip and in vitro and in vivo gene expression
microarray data from this publication are available from
GEO under the accession number Series GSE34277, consist-
ing of three constituent datasets GSE34270, 34271, 34276.
Statistics
Statistical analyses of experimental data were done in
GraphPad Prism 5.0 (GraphPad Software Inc., San Diego,
CA, USA) unless otherwise indicated.
Results
Smad3 mediates TGF-β-induced tumor suppression in a
model of breast cancer progression
To address the role of TGF-β at different stages of
breast cancer progression, we have used four MCF10A-
derived cell lines developed by Miller and co-workers
[37,38], as schematized in Figure 1A. Although the par-
ental nontumorigenic MCF10A cell line is ER negative,
the derivative cell lines show varying degrees of ER posi-
tivity and biological responses to estrogen in vitro and
in vivo, and have other characteristics of ER+ breast can-
cer (see Methods). Using a dnTβRII to block TGF-β sig-
naling in vivo, we previously showed that TGF-β acts as
a tumor suppressor in M2 and M3 cells, but not in the
closely related M4 cells where TGF-β now acts as a me-
tastasis promoter [25]. Thus in the transition from M3
to M4 the tumor suppressive responses are selectively
lost, and the model system provides a valuable platform
for the identification of genes specifically involved in
TGF-β-driven tumor suppression.
To identify genes at the core of the tumor suppressor
program, we decided to focus on direct transcriptional tar-
gets of TGF-β, reasoning that hierarchically these would
be the most upstream regulators of the program. In the
canonical TGF-β signaling pathway, binding of TGF-βs to
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Figure 1 Smad3 mediates tumor suppression by TGF-β in the MCF10A model of breast cancer progression. (A) Schematic illustration of
the MCF10A-based xenograft model of breast cancer progression. TGF-β has tumor-suppressor activity in M3 cells but this effect is lost in M4 cells
and instead TGF-β promotes metastasis. (B) Knockdown of Smad2 and Smad3 protein in M3 and M4 cells was verified by Western blot, quantitated
relative to the β-actin loading control and normalized relative to the shGFP condition for each cell line. (C) Relative contributions of Smad2 and Smad3
to the tumor-suppressive effect of TGF-β. Mice were orthotopically implanted with M3 cells or M4 cells, genetically modified to stably express shSmad2,
shSmad3 or the control shGFP, and tumor volumes were assessed after seven weeks (M3) or four weeks (M4). Bars indicate median +/−interquartile
range; P <0.05 was statistically significant, Mann-Whitney U test. ns, not significant. (D) Kinetics of Smad3 phosphorylation. Western blot of total Smad3
protein and C-terminal phosphorylated Smad3 (Smad3-CP) levels at various time points after TGF-β treatment in M1 to 4 cells. Total Smad3 is shown
for t = 0 h. (E) Western blot showing linker phosphorylated Smad3 (Smad3-LP) at 1 hour after treatment with 2 ng/ml TGF-β. TGF-β, transforming
growth factor beta.
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http://breast-cancer-research.com/content/16/3/R57activation of the signal-transducing components Smad2
and Smad3, which translocate to the nucleus and regulate
gene expression. While TGF-β can signal through non-
canonical pathways, canonical Smad signaling is thought
to be central to TGF-β-driven tumor suppression [66].
Smad2 and Smad3 are highly homologous, but may play
non-redundant or even opposing roles in TGF-β signaling
[67], so we first wished to determine which Smad was
more important for tumor suppression in the MCF10-
based breast cancer model. Using shRNA knockdown, we
found that Smad3 but not Smad2 mediates the TGF-β-
induced tumor suppressive responses in M3 tumors, and
this tumor suppressive effect of Smad3 was lost in the
more malignant M4 cell line (Figure 1B,C). We then
showed that loss of tumor suppression in M4 was not due
to changes in Smad3 expression, or duration or extent of
Smad3 C-terminal phosphorylation (Figure 1D), which
were similar between all four cell lines. Input from other
signaling pathways can lead to phosphorylation of Smads
on the middle linker region, resulting in loss of select
tumor suppressive responses [68]. However, basally high
levels of linker phosphorylation of Smad3 were already
evident in the malignant M3 cells, which nevertheless
still retain their tumor suppressive responses to TGF-β
(Figure 1E), so loss of tumor suppression in M4 cells
cannot be due to de novo Smad3 linker phosphoryl-
ation. The level of Smad3 linker phosphorylation in M3
varied somewhat between experiments but was always
much greater than in M1 and M2, and was either
slightly less than or similar to that in M4. Thus we rea-
soned that events downstream of Smad3 activation are
primarily responsible for the loss of tumor suppression
in M4 cells.
Promoter-wide analysis shows major changes in Smad3
binding patterns with cancer progression
We next hypothesized that loss of tumor-suppressive activ-
ity is caused by changes in the spectrum of TGF-β/Smad3
target genes with increasing tumor progression. We there-
fore performed promoter-wide ChIP-chip analysis using a
Smad3-specific antibody (Figure 2A) to identify TGF-β/
Smad3 target genes. This antibody immunoprecipitated
target DNA from a known Smad3 binding region in the
Smad7 promoter in Smad3 wild-type but not Smad3 null
mouse mammary epithelial cells (Figure 2B). In the human
breast cancer cell lines, we showed that Smad3 binding to
known target sites in the promoters of the SMAD7,
COL7A1, and SERPINE1 genes in M3 cells was maximal
by 1 hour after TGF-β addition, so this time point was se-
lected for the ChIP-chip analysis (Figure 2C). Parallel gene
expression studies were performed at both 1 hour and 6
hours after TGF-β addition.
Smad2 and Smad3 can be activated by other TGF-β
superfamily members such as the activins [3], as well asby the unrelated kinases Mps1 [69], WNK1 [70] and
MPK38 [71], and by advanced glycation end products
[72]. In order to focus specifically on TGF-β-driven
Smad3 binding, we filtered the ChIP-chip data for loci
that showed differential Smad3 occupancy between the
untreated and TGF-β-treated states, rather than just
analyzing the treated state as has been done previously
[73-75]. This strategy yielded 498 TGF-β-induced Smad3
binding regions (SBR) corresponding to 404 annotated
genes across all four cells (Additional file 4). Representa-
tive results for IFNK, a novel gene target that only
shows Smad3 binding in M1 and M2 cells, are shown
in Figure 2D,E. As expected, the canonical Smad3 bind-
ing motif GTCT, or its reverse complement AGAC,
were significantly enriched within the SBRs (Figure 2F),
though the most enriched transcription factor motifs
were those of the AP-1 family (Figure 2G), with Smad
motifs frequently co-occurring with AP-1 family motifs
in the SBRs (Figure 2H). Enrichment of AP-1 motifs in
Smad2/3 binding regions was previously also observed
in keratinocytes [73], and probably reflects the ability of
Smads to bind directly to the AP1 motif binding site
through TGF-β-inducible interactions of Smad3 with c-
Fos, c-Jun or Fra1 [76,77].
Despite the close genetic relatedness of MCF10-
derived cell lines, relatively few Smad3 target genes (37/
404 = 9.2%) were common to all four lines, with the ma-
lignant M3 and M4 cells showing a particularly high
proportion of unique targets (Figure 3A and Additional
file 4). ChIP-QPCR validation at 25 loci in all four cell
lines was performed that broadly confirmed this unex-
pected finding (Additional file 5). Furthermore, global
TGF-β-regulated gene expression showed a similar pat-
tern, with large numbers of unique gene targets in the
four cell lines (Additional file 6), confirming that the ob-
servation of cell-line dependent gene occupancy and
regulation in response to TGF-β/Smad3 is not due to
low sensitivity of the ChIP analysis but instead reflects a
fundamentally important feature of TGF-β biology. To
determine the basis of this phenomenon, we selected 10
target genes representing different patterns of TGF-β-
induced Smad3 occupancy across the four cell lines
(Figure 3B), and determined whether there were differ-
ences between the cell lines in local DNA methylation
and chromatin activation state at the SBRs. We found
that the target promoters were all hypomethylated in
all four cell lines (Figure 3C), so occupancy patterns
could not be explained by differential promoter methy-
lation. However, TGF-β only induced Smad3 occupancy
at SBRs in regions of chromatin that were activated
prior to TGF-β treatment, as assessed by ChIP for the
presence of H3AcK9/14 at the SBR in the untreated state
(Figure 3D). Thus the spectrum of TGF-β-induced Smad3


























































































































































Figure 2 Identification of Smad3 target genes by ChIP-chip in the MCF10A progression series. (A) The anti-Smad3 antibody recognizes a
unique band in wild type and Smad2 null but not Smad3 null IMECs by Western blot. (B) ChIP-QPCR showing ability of Smad3 antibody (αS3) to
immunoprecipitate Smad3 bound to the Smad7 promoter in Smad3 wild-type but not Smad3 knockout mouse embryo fibroblasts. CON, isotype-
matched control antibody. (C) Time course of Smad3 occupancy at promoters of three previously characterized Smad3 target genes assessed by
ChIP-QPCR following treatment of M3 cells with TGF-β. (D) Genome browser view (hg18) of Smad3 binding in the promoter of IFNK in M1 to M4
cells. The signal represents the difference between the TGF-β-treated and untreated conditions. The threshold represents signal intensity corresponding
to FDR = 0.15. Black rectangles represent regions of significant Smad3 binding. (E) ChIP-QPCR validation of Smad3 occupancy at the IFNK locus. Results
are mean +/−SD (n = 3) normalized to no TGF-β condition. *P <0.05 for enrichment >2-fold. (F) Enrichment of the canonical Smad binding element
(SBE) in SBRs. The black line represents 190 high confidence SBRs and the grey line represents 190 random promoter regions with no Smad3
binding. The generic SMAD binding motif is shown. (G) Top 10 enriched transcription factor (TF) matrices within +/−250 bp of the center of
190 high confidence SBRs. (H) Schematic showing co-occurrence for the most enriched TF motifs. Pairwise analysis of each enriched motif was
performed using the Fisher’s exact test with Bonferroni correction. The adjusted P values for co-occurrence of pairs of TFs are represented by the
connecting lines: P <1e-7 (purple), P <1e-5 (pink), P <1e-2 (black). ChIP, chromatin immunoprecipitation; FDR, false discovery rate; IMEC, immortalized
mouse mammary epithelial cells; QPCR, quantitative polymerase chain reaction; SBR, Smad binding region; TGF-β, transforming growth factor beta.

























































































































































Figure 3 Smad3 binding differs widely across the progression
series. (A) Petal plot showing the overlap in Smad3 target genes
between the different cell lines. The genes involved are given in
Supporting Information Table S1 in Additional file 4. (B) Representative
genes with distinct Smad3 occupancy patterns as confirmed by
ChIP-QPCR. Closed circles indicate TGF-β-induced Smad3 occupancy.
(C) DNA methylation status at promoter regions of each target gene in
(B) as determined by MeDIP-QPCR. Relative enrichment in the bound
(MeDIP) vs. unbound fractions is shown. PPIA and MyoD were controls
for unmethylated and highly methylated DNAs respectively. (D) QPCR
quantitation of target enrichment following ChIP using anti-H3AcK9/14
to identify active chromatin. Enrichment at the SBR was calculated
relative to input DNA. PPIA and MyoD were controls for active and
inactive promoters respectively. Active chromatin has an enrichment
value >1.00 (indicated by threshold line). ChIP, chromatin
immunoprecipitation; H3AcK9/14, histone H3 acetylated on lysine
9 or 14; MeDIP, methylated DNA immunoprecipitation; QPCR,
quantitative polymerase chain reaction; SBR, Smad binding region;
TGF-β, transforming growth factor beta.
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observation identifies one molecular mechanism that may
contribute to the well-known contextuality of TGF-β action.
Identification of Smad3 target genes that contribute to
the tumor suppressive effects of TGF-β
Having identified a set of core TGF-β/Smad3 target
genes in the breast cancer model system using the ChIP-
chip approach, we next determined which of these were
specifically important for the tumor suppressive func-
tions of TGF-β by assessing gene expression. Microarray
analysis of gene expression in vitro (using a P value cut-
off of <0.001 for differential expression between the
TGF-β-treated and untreated conditions) revealed that
approximately 50% of the Smad3 occupied genes in each
of the cell lines showed altered gene expression within 6
hours after TGF-β treatment (Additional file 7). Since
the tumor-suppressive effect of TGF-β is lost on pro-
gression from M3 to M4 cells, we focused our subse-
quent analysis on these two lines in order to develop a
TGF-b/Smad3 tumor suppressor signature (TSTSS), as
schematized in Figure 4. First, we compared patterns of
TGF-β-regulated expression of Smad3 target genes
in vitro, reasoning that genes that were regulated in M3
only should be enriched for Smad3-driven tumor-
suppressive responses. Unsupervised hierarchical cluster-
ing of genes that were heterogeneously expressed across
the four conditions (Figure 5A) revealed sets of Smad3
target genes that were (a) uniquely upregulated by TGF-
β in M3 (Cluster I: 38 genes total); (b) similarly regu-
lated by TGF-β in M3 and M4 (Clusters III and IV: 65
genes total); and (c) not regulated by TGF-β but basally
different between the two cell lines; Clusters II and V).
No distinct clusters of Smad3 target genes that were
uniquely regulated in M4 cells were identified.
TGF-β effects are highly context dependent, and the
in vivo microenvironment provides a different set of
contextual cues that could affect gene expression. To
ask whether the 38 Smad3 target genes that were
uniquely upregulated by TGF-β in M3 cells in vitro were
also regulated by TGF-β in vivo, we next analyzed gene
expression in M3 tumors with and without TGF-β path-
way ablation using a dnTβRII [65]. Microarray analysis
of these tumors showed that 26/38 (77%) of the M3
unique targets were also regulated by TGF-β in vivo, a
finding that was confirmed by RT-QPCR (Figure 5B).
Unexpectedly, nearly 25% of these genes were regulated
in the opposite direction by TGF-β in vitro and in vivo,
including the hallmark TGF-β response genes SERPINE1
and ANGPTL4 (Figure 5B). Since this was a surprising
result, we then wished to determine whether the dis-
cordant in vitro/in vivo results reflected an involvement
of alternative TGF-β signaling pathways other than
Smad3 in regulation of the discrepant genes in the
Core TGF-β/Smad3 targets
in M3 and M4 cells
In vitro gene expression filter 















TGF-β/Smad3 tumor suppressor signature “TSTSS”
Smad3 ChIP-chip
Microarray
Microarray + QRT-PCR validation
Direct TGF-β targets
Figure 4 Strategy for integration of ChIP-chip and gene expression datasets to generate a core TGF-β/Smad3 tumor suppressor signature.
The experimental strategy for identification of the TGF-β/Smad3 tumor suppressor signature (TSTSS) is shown. ChIP, chromatin immunoprecipitation;
TGF-β, transforming growth factor beta.
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concordantly (ANXA2, PTPN3, SERPINE2) or discord-
antly (ANGPTL4, KLF7, SERPINE1) regulated between
the in vitro and in vivo conditions and analyzed expres-
sion of the same genes in M3 tumors with and without
Smad3 knockdown. The results were consistent with a
role for Smad3 in the in vivo setting as well as in vitro
(Figure 5C). Thus TGF-β signaling through Smad3 can
upregulate or repress the same target genes in a given
cell line depending on the local microenvironmental
context (in vitro vs. in vivo). To confirm that the dis-
crepancy in direction of target gene regulation in vitro
and in vivo was not due to major contributions from the
stroma in the tumors in vivo, we immunostained M3 tu-
mors for ANGPTL4 and SERPINE1 and showed that
these proteins were expressed predominantly in the tumor
parenchyma (Additional file 8). The data emphasize the
critical importance of including an in vivo gene expression
filter in this type of approach, since clearly the directionalityof Smad3 target gene regulation in vivo cannot reliably be
extrapolated from in vitro results.
TGF-β/Smad3 target genes associated with tumor
suppression predict good clinical outcome in human
breast cancer datasets
Taking the core list of 26 genes that survived the
in vivo filter, we next asked whether this TSTSS was as-
sociated with clinical outcome in human breast cancer
datasets. Using the GOBO software [56], which allows a
directional weighting (upregulated vs. downregulated)
to be assigned to individual genes in a gene set, we per-
formed a meta-analysis of the TSTSS in eight clinical
breast cancer gene expression datasets that used the
Affymetrix array platform. Twenty out of the 26 genes
of the TSTSS were represented in the GOBO clinical data-
sets (Additional file 9A). High expression of the TSTSS
was strongly associated with better distant metastasis-free

















(i) M3 in vitro +/- TGF-β
(ii) M3 in vivo +/- dnTβRII
(iii) M3 in vivo +/- shSmad3
Low TGF-β signaling condition












































































































































































dnTβRII: Low TGF-β condition




- -+ + TGF-β
M3 cells M4 cells
Induced in M3 only
Not regulated by TGF-β
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Not regulated by TGF-β
Figure 5 Generation of core TGF-β/Smad3 tumor suppressor signature. (A) Unsupervised hierarchical clustering of differentially expressed
Smad3 target genes in M3 and M4 cells treated with TGF-β in vitro for 6 hours. The 38 genes induced by TGF-β in vitro in M3 only were taken forward
for further analysis. (B) RTQ-PCR validation of the 26 genes out of the original 38 genes that microarray analysis showed to be also regulated by TGF-β
in M3 tumors in vivo. M3 tumors transduced with the dnTβRII represents the low TGF-β signal condition in vivo, while M3 tumors transduced
with control lentivirus represents the high TGF-β signal condition in vivo. Expression was normalized to the low signal condition for each gene.
Results are the mean +/−SEM for three tumors/experimental group. The difference between the high and low TGF-β signaling conditions is
statistically significant (P <0.05; unpaired t test) for all genes shown. Note the six genes, marked by arrows, which are downregulated by TGF-β
in vivo whereas they were upregulated in vitro. (C) Smad3 dependence of TGF-β regulation of select target genes in vivo. Further RT-QPCR
quantitation was performed for six representative genes under the following conditions: (i) M3 cells treated with 5 ng/ml TGF-β (high TGF-β signal
condition) or vehicle (low signal condition) in vitro; (ii) M3 tumors in vivo following transduction with a dnTβRII to block all TGF-β responses
(low signal condition) or LacZ control lentivirus (high signal condition); (iii) M3 tumors in vivo following transduction with shSmad3 to block
Smad3-mediated responses (low signal condition) or shGFP control lentivirus (high signal condition). Results are mean +/−SEM for three to six
independent samples/group, normalized to low signaling condition. *statistically significant (P <0.05) for high vs. low signaling condition,
unpaired t test. dnTβRII, dominant-negative type II TGF-β receptor; TGF-β, transforming growth factor beta.
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weighting for expression of the signature genes was
used (Figure 6A). Notably, the prognostic power of the
signature was greatly decreased (P = 0.05) if weighting was
used corresponding to the in vitro rather than in vivodirection of gene regulation (Figure 6B), thus demonstrat-
ing the utility of our integrated in vitro/in vivo approach.
Permutation analysis in the GSE6532 dataset showed
that the in vivo TSTSS combination outperformed 97%
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Figure 6 Meta-analyses correlating TGF-β/Smad3 target genes with outcome in human breast cancer datasets. Kaplan-Meier analyses
were performed using the online GOBO tool to assess the association of the TGF-β-regulated gene sets with distant metastasis-free survival (DMFS) in
meta-analyses across multiple breast cancer cohorts (1,379 tumors from eight datasets). Patient datasets were dichotomized to higher than median
expression (black) or lower than median expression (grey) of the gene set. P values were determined by the log-rank test. (A,B) Kaplan-Meier plots for
survival of all patients in the GOBO datasets, using the set of TGF-β/Smad3 target genes that were uniquely regulated in M3 (the TSTSS). This gene set
was designed to be enriched in genes involved in tumor suppression. Weighting (positive or negative) of individual target genes is based on
the directionality of TGF-β-regulated gene expression observed in M3 tumors in vivo (A) or in M3 cells in vitro (B) as indicated. (C,D) Correlation of the
TSTSS (using the in vivo directional weighting) with DMFS in ER+ (n = 856) (C), and ER- (n = 320) (D) patient subsets of the GOBO cohorts. ns,
not significant. ER, estrogen receptor; GOBO, gene expression-based outcome for breast cancer online; TGF-β, transforming growth factor beta;
TSS, transcriptional start site; TSTSS, TGF-β/Smad3 tumor suppressor signature.
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random binary weight vectors (see Methods for more de-
tails). Furthermore, the prognostic power of the in vitro/
in vivo concordant and discordant gene sets when ana-
lyzed separately was much lower than that of the full
TSTSS (Additional file 10). Using an identical strategy to
that used to generate the TSTSS, we derived a ‘generic’
TGF-β signature from the 65 Smad3 target genes that were
regulated by TGF-β in both M3 and M4 in vitro, of which
24 genes survived the in vivo filter (Additional file 9B). As
expected, this signature performed much less well than did
the TSTSS (Additional file 11), which highlights the import-
ance of enriching the signature for genes functionally
associated with tumor suppression in order to make theTGF-β-driven tumor suppressive signal detectable in clinical
samples. It should be noted that TGF-β also functions as a
tumor suppressor in premalignant M2 cells [25], but the
TSTSS is not evident in M2 cells (not shown). We believe
this is because TGF-β likely suppresses the premalignant-to-
malignant transition (M2) and tumor progression (M3) by
different mechanisms. Since the patient datasets represent
tumors from later stages in progression, here we focused
specifically on the M3 tumor-suppressor signature.
Consistent with our use of an ER+model to generate
the signature and our observations of the strong contex-
tuality of TGF-β-regulated gene expression, the prognostic
power of the in vivo-weighted TSTSS was restricted to the
ER+ tumors only in the GOBO datasets (Figure 6C,D). In
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lower than median expression of the TSTSS was associ-
ated with increased risk of distant metastasis (hazard
ratio = 1.85, confidence interval = 1.28 to 2.67; P = 0.001;
n = 553 evaluable patients), independent of lymph node
status, tumor grade, age at diagnosis and tumor size. The
signature also prognosticated in three independent co-
horts of ER+ breast cancer patients: the NKI cohort using
custom spotted cDNA arrays [58], and the TCGA cohort
[78] and BT2000/Metabric cohorts [79] both using Illu-
mina arrays (Additional file 12). Thus performance of the
signature is robust across different datasets and array plat-
forms. Our data suggest that TGF-β/Smad3-mediated
tumor-suppression plays an important role in the natural
history of ER+ breast cancer, and that tumor-suppressive
effects of TGF-β are still evident in the tumor at the time
of surgery and influencing disease outcome for a signifi-
cant fraction of patients.
TGF-β/Smad3 effects on tumor cell proliferation and
differentiation in breast cancer
We next asked what biological activities might underlie
the tumor-suppressive effects of TGF-β/Smad3 in breast
cancer. Inhibition of epithelial cell proliferation is a hall-
mark activity of TGF-β [3], and we have previously
shown that TGF-β strongly inhibits proliferation of M3
cells but not M4 cells in vitro [25]. Furthermore, the
prognostic power of many breast cancer signatures is
driven by proliferation [80]. To address the relationship
between the TSTSS and proliferation in the clinical
breast cancer datasets, we used a meta-PCNA index as a
surrogate for proliferation [60]. There was a weak but
highly statistically significant negative correlation be-
tween the metaPCNA index and the TSTSS in ER+
breast tumors but not ER- tumors in multiple independ-
ent cohorts. Results for the TCGA cohort are shown in
Figure 7A. Similar results were obtained for ER+ tu-
mors in the GSE6532/Loi and NKI cohorts (Additional
file 13). These results suggest that antiproliferative ef-
fects of TGF-β are still active in ER+ tumors. However,
the TSTSS still prognosticated independently of prolif-
eration in multiple independent datasets by multivariate
analysis (Table 1), suggesting that the tumor-suppressive
effects of TGF-β in ER+ breast cancer must also involve
additional biological mechanisms.
In ER+ tumors, GOBO meta-analysis showed that
the TSTSS was inversely correlated with tumor grade
(P = 0.00001; Figure 7B), which in part reflects histo-
logic differentiation [81]. A total of 7/26 genes of the
TSTSS were annotated for involvement in cellular dif-
ferentiation (ANXA2, CTGF, EFNA1, ITGA4, LAMB3,
PTPN11, SPAG9), and we also found that the TSTSS was
weakly positively correlated in ER+ but not ER- tumors
with a meta-differentiation index (see Methods fordefinition) that reflects luminal differentiation (Figure 7C).
To demonstrate a causal role for TGF-β/Smad3 in regulat-
ing breast cancer differentiation, we showed that knock-
down of Smad3, but not Smad2, was associated with
reduced development of well-differentiated glandular-like
structures in M3 tumors (Figure 7D,E), and a significant
reduction in expression of the differentiated luminal
markers cytokeratin 8 (CK8) and ER (Figure 7D,F). Thus
the tumor-suppressive effects of TGF-β in ER+ breast can-
cer include a role in enhancing cellular differentiation, and
Smad3 is a critical mediator of this activity.
Ephrin signaling contributes to tumor-suppressive effects
of TGF-β in ER+ breast cancer
To begin to explore molecular mechanisms underlying
TGF-β-driven tumor suppression, we performed Ingenuity
Pathway Analysis on the signature genes. Network analysis
was relatively uninformative for this small number of
genes and did not provide any useful leads other than in-
dicating that a number of the signature genes were subject
to regulation by ubiquitination (Additional file 14). How-
ever, pathway analysis identified ephrin receptor sig-
naling as the most enriched pathway in the TSTSS
(Figure 8A), with the genes involved being EFNA1,
ITGA4, LIMK2 and PTPN11. The ephrin ligands and
ephrin receptors are a large family of membrane-bound
proteins that signal bidirectionally in a cell-contact-
dependent manner. Ephrin-A1 (EFNA1) ligand binding to
the EphA2 receptor at sites of cell-cell contact maintains
epithelial phenotype and integrity in part by downregulat-
ing Akt, Rho/Rac and Ras pathway signaling [82-84]. In
contrast, unligated EphA2 becomes phosphorylated by
Akt on Ser897. This phosphorylation event results in
loss of suppressive effects on the Ras/Erk pathway and
enhanced pro-oncogenic signaling through Akt and
Rac1, ultimately leading to increased cell migration, in-
vasion, proliferation and survival [84]. Thus depending
on the balance of ligand and receptor, ephrin pathway
signaling can be associated with pro-oncogenic or anti-
oncogenic outcomes.
To investigate the interrelationship between ephrin
signaling and TGF-β, we generated a metaEphrin index
consisting of the top 30 genes most highly correlated with
EFNA1 mRNA in normal human tissues, and we showed
that this index was strongly positively correlated with the
TSTSS in ER+ breast cancer datasets (see Figure 8B for
the TCGA cohort; similar results were also seen for the
GSE6532 and NKI cohorts in Additional file 13). The
index was also weakly associated with good outcome in
ER+ breast cancers by GOBO meta-analysis (Figure 8C),
suggesting that ephrin pathway signaling might contribute
to the tumor-suppressive effects of TGF-β in ER+ breast
cancer. Using ChIP-QPCR, we confirmed that TGF-β
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Figure 7 Loss of TGF-β signaling leads to reduced tumor differentiation. (A) The TSTSS is weakly anticorrelated with proliferation, as assessed
using a metaPCNA index, in ER+ but not ER- breast cancers (TCGA cohort). (B) Expression of the TSTSS inversely correlates with tumor grade in ER+
breast cancer (n = 904 patients), as assessed using GOBO tool. (C) Correlation between the TSTSS and luminal differentiation, as assessed using
a meta-differentiation index, in ER+ and ER- tumors in the TCGA cohort. (D) Immunohistochemical staining of cytokeratin 8 (CK8) and ER-α in
primary tumors from M3 cells expressing shGFP, shSmad2 or shSmad3. Scale bars represent 100 μm. (E) Quantitation of % area occupied by
structures with a differentiated glandular histology in M3 tumors expressing shGFP (control), shSmad2 or ShSmad3. Results are mean +/−SEM
for five tumors/group. (F) Quantitation of CK8 and ER staining was performed using Image-Pro Plus software. Each datapoint represents the
mean of five fields/tumor, and results are shown as mean +/−SEM for five tumors/group. *P <0.05 for one-way ANOVA with Dunnett’s multiple
comparison test; ns, not significant; hpf, high power field. ER, estrogen receptor; GOBO, gene expression-based outcome for breast cancer
online; TGF-β, transforming growth factor beta; TSTSS, TGF-β/Smad3 tumor suppressor signature.
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reflecting a more active state of the chromatin at the
EFNA1 promoter in M3 than M4 cells under basal condi-
tions (Figure 8E). As expected, EFNA1 mRNA expressionwas upregulated by TGF-β treatment in M3 and not M4
cells (Figure 8F). Upregulation of Ephrin-A1 protein by
TGF-β in M3 cells in vitro was confirmed by Western
blot and was associated with a corresponding decrease
Table 1 Prognostic power of the TSTSS in three independent ER+ breast cancer datasets
Breast cancer cohort
GSE6532 (Loi) NKI TCGA
Variable Ref for HR = 1 Hazard ratio CI P value Hazard ratio CI P value Hazard ratio CI P value
TSTSS High 1.89 1.1-3.27 0.02211 1.81 1.12-2.93 0.01535 2.6 1.21-5.58 0.0142
metaPCNA Low 2.32 1.27-4.24 0.006251 1.67 0.96-2.92 0.07143 0.77 0.38-1.58 0.4788
Age Low* 1.03 0.63-1.69 0.9 0.52 0.32-0.84 0.007841 1.88 0.94-3.75 0.07393
Node Negative 0.91 0.54-1.53 0.7113 0.84 0.52-1.34 0.4651 2.33 1.07-5.08 0.03389
Grade Grade 1 0.99 0.67-1.47 0.9798 1.57 1.1-2.25 0.01365 na na na
Size Continuous 1.33 1.09-1.62 0.005177 1.22 0.95-1.57 0.1109 na na na
Multivariate analysis was performed using the Cox proportional hazards model. Nineteen out of the 26 genes of the TSTSS were found in the GSE6532 (Loi) and
NKI cohorts, and 24 out of 26 genes were found in the TCGA cohort. The TSTSS was analyzed as a binary variable where high indicates higher than median
expression. The hazard ratio refers to distant metastasis-free survival for GSE6532 and NKI, and overall survival for TCGA. The metaPCNA index is a surrogate for
proliferation and low indicates lower than median expression. Parameters for the TSTSS are highlighted in bold. *Low is ≤61 yrs (GSE6532); ≤45 yrs (NKI); ≤60 yrs
(TCGA). HR, hazard ratio; CI, confidence interval; TSTSS, TGF-β/Smad3 tumor suppressor signature; na, not available.
Sato et al. Breast Cancer Research 2014, 16:R57 Page 17 of 23
http://breast-cancer-research.com/content/16/3/R57in pro-oncogenic phosphorylation of the receptor EphA2
on Ser897 (Figure 8G). Thus by upregulating Ephrin-A1,
TGF-β treatment can repress pro-oncogenic signaling
through the ephrin pathway in M3 cells. To demonstrate
a functional role for Ephrin-A1 in tumor suppression,
we used shRNA knockdown in M3 cells (Figure 8H)
and showed that ephrin-A1 knockdown significantly in-
creased primary tumorigenesis (Figure 8I). Thus activa-
tion of Ephrin-A1 signaling by TGF-β may contribute
to the tumor-suppressive effects in ER+ breast cancer.
Discussion
The highly pleiotropic nature of the TGF-β signaling path-
way creates significant hurdles that must be overcome be-
fore the complex roles of this pathway in tumorigenesis
can be understood and therapeutically exploited in breast
cancer. Our integrated genomic approach is the first that
specifically isolates the tumor-suppressive gene expression
responses to TGF-β from the tumor-promoting or
tumor-unrelated responses, and our results suggest that
TGF-β-driven tumor-suppressive responses contribute
importantly to good clinical outcome in a subset of pa-
tients with ER+ breast cancer. A number of interesting
features of TGF-β tumor biology were uncovered in
this study and the broader implications are discussed
further below.
Previous genome-wide ChIP studies have shown con-
siderable differences in Smad target genes between cell
lines of different origins [73,74,85]. However, here we
found that the spectrum of Smad3 target genes differed
to a surprising extent between four highly related breast-
derived cell lines, the parental MCF10A line (M1) and
its three premalignant or malignant derivatives (M2, M3,
M4), despite their common origin and identical test con-
ditions. Furthermore, we showed that TGF-β-induced
Smad3 binding occurred in regions of chromatin that
were already activated prior to TGF-β treatment, sug-
gesting that the spectrum of Smad3 binding is highlysensitive to preexisting local differences in the epigenetic
landscape. This feature of Smad3 effector activity may
contribute significantly to the known contextuality of
TGF-β action, and raises the possibility that TGF-β-
induced Smad3 promoter occupancy mostly serves to
fine-tune ongoing transcriptional programs in this model
rather than initiating new programs. Consistent with this
hypothesis, it was recently shown that during embryonic
development Smad3 binds primarily to promoter regions
that are already occupied by the master transcription
factors for the developmental stage or lineage [86].
Our novel observation that the direction of regulation
of Smad3 target genes by TGF-β can differ in vitro and
in vivo identifies an additional new facet of TGF-β
contextuality that is highlighted by the effects of TGF-β
on ANGPTL4. ANGPTL4 was previously identified as a
metastasis-promoting gene that was upregulated by
TGF-β in MDA-MB-231 cells, an ER-negative breast
cancer model in which TGF-β has lost its tumor-
suppressive activity and instead promotes progression
[34]. While ANGPTL4 was upregulated by TGF-β in
both MDA-MB-231 and M3 cells in vitro, we found
that ANGPTL4 was actually downregulated by TGF-β/
Smad3 in vivo in the M3 tumors where TGF-β func-
tions as a tumor suppressor. This is in contrast to the
upregulation in vivo of ANGPTL4 in MDA-MB-231
tumors where TGF-β functions as a pro-progression
factor. Thus the in vitro condition serves to identify
TGF-β target genes, but it does not indicate the direc-
tion of their regulation in the in vivo context and hence
cannot predict the critical issue of biological outcome
(tumor suppression vs. tumor progression). Identifying
the factor that causes the direction of expression of cer-
tain Smad3 target genes to flip in vivo will be an inter-
esting challenge for the future.
Our integrated genomic strategy allowed us to dissect
out a core TGF-β/Smad3 gene signature that specific-
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Figure 8 Ephrin signaling contributes to the tumor suppressive effects of TGF-β in ER+ breast cancer. (A) Pathway enrichment in the TSTSS
assessed by Ingenuity Pathway Analysis. Fisher’s exact test with Benjamini-Hochberg (B-H) correction. The dotted line represents the P <0.05 significance
threshold. (B) Correlation of TSTSS with meta-EFNA index in ER+ tumors of the TCGA cohort. (C) Association of meta-EFNA index with distant
metastasis-free survival (DMFS) in ER+ breast cancer (n = 856 patients) using the GOBO tool. (D) Smad3 ChIP-QPCR at the EFNA1 locus in M3
and M4 cells. (E) ChIP-QPCR for H3AcK9/14 at the EFNA1 locus to identify active chromatin. (F) Time course of EFNA1 mRNA induction by
TGF-β (2 ng/ml) in M3 and M4 cells. Results are mean +/−SEM of three determinations. *P <0.05. (G) Western blot of effect of TGF-β treatment
of M3 cells on Ephrin A1 (EFNA1) expression and oncogenic signaling through phosphorylation of the EphA2 receptor on S897. EFNA-Fc was
used as a positive control for activation of the EphA2 signaling path. (H) Western blot showing knockdown of EFNA1 in M3 cells. (I) Knockdown of
EFNA enhances tumorigenesis in M3 cells. n = 8 to 10 mice/group. *P >0.05 one-way ANOVA, Tukey’s multiple comparison test. ChIP, chromatin
immunoprecipitation; ER, estrogen receptor; GOBO, Gene expression-based Outcome for Breast cancer Online; H3AcK9/14, histone H3 acetylated
on lysine 9 or 14; QPCR, quantitative polymerase chain reaction; TGF-β, transforming growth factor beta; TSTSS, TGF-β/Smad3 tumor suppressor signature.
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tiple independent ER+ breast cancer cohorts. In multivari-
ate analysis, below-median expression of the signature
was associated with a two-fold increased hazard ratio for
development of distant metastases. This finding strongly
suggests that the tumor suppressive effects of TGF-β per-
sist and limit progression in a significant fraction of
breast cancers at the time of clinical intervention. Im-
portantly, our TGF-β/Smad3 signature only prognosti-
cated well when the signature genes were weighted for
the direction of regulation that was seen in vivo and
not in vitro. Thus two key features of our approach were
critical for identifying a discernable tumor suppressorsignal for TGF-β in the clinical datasets. One was the use
of closely related breast cancer cell lines with and without
an intact tumor-suppressive response so that TGF-β-
regulated genes that were specifically involved in tumor
suppression could be readily identified, and the other was
the coupling of the in vitro discovery steps with in vivo
validation. Prognostic TGF-β signatures have previously
been generated through strategies that did not explicitly
separate the different activities of TGF-β [11,32,34,36]. Al-
most universally, the signatures are associated with poor
outcome in breast cancer patients, suggesting that they
primarily capture the pro-oncogenic effects of TGF-β
[18,32,34,36]. In the one exception, a TGF-β signature
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type and TGFBR2 knockout mouse mammary tumor
cells weakly correlated with good outcome in ER+
breast cancers [11]. However, there is little overlap be-
tween this signature and our own, suggesting that the
different approaches used are capturing complementary
aspects of the underlying TGF-β biology. Thus the
TGFBR2-based signature implicates TGF-β in the
suppression of local inflammation in the tumor micro-
environment [11], whereas ours highlights tumor
cell-autonomous effects of TGF-β on tumor cell prolifera-
tion and differentiation (see later).
We found that high expression of our TGF-β/Smad3
tumor-suppressor signature was associated with good
outcome only in patients with ER+ tumors, suggesting
that TGF-β plays a particularly important role in limiting
progression of this breast cancer subtype. Consistent
with these results, TGF-β1 was previously identified as a
differentially expressed hub in gene expression networks
derived from normal luminal ER+ breast epithelial cells,
but not from ER- cells [87], and TGF-β was shown to re-
strain the proliferation of ER+mammary cells in normal
mice [88]. Interestingly however, we found higher overall
expression of the signature genes in ER- breast cancer
(Additional file 15), although no association with clinical
outcome was observed in this tumor subtype. This ob-
servation suggests that that the TGF-β/Smad3 tumor-
suppressor program, while still detectable, has been
functionally overridden or subverted by the oncogenic
pathways that are activated in ER- tumors. It is currently
not clear whether TGF-β has distinct tumor-suppressive
effects in ER- tumors that are not captured by our signa-
ture, since our signature was developed using an ER+
model. However, given our demonstration of the strong
context dependence of Smad3 binding and thus of TGF-
β effects, we believe that there may not be a universal
signature for TGF-β-driven tumor suppression. Thus the
very important goal of developing gene signature-based
predictive biomarkers for patient inclusion/exclusion
from clinical trials with TGF-β antagonists is a challen-
ging one, and our data suggest that such signatures will
likely have to be tailored to the specific tumor subtype.
Based on our current findings, we propose that patients
with ER+ tumors and high signature expression would
not be good candidates for TGF-β antagonist therapy,
but that the mere presence of this particular TGF-β tumor-
suppressor signature in ER- breast cancer patients would
not necessarily be a contraindication for such therapy.
Further analysis of our signature gave insights into
the mechanisms of tumor suppression by TGF-β in
breast cancer. High expression of the signature was in-
versely correlated with proliferation index and tumor
grade, suggesting that the known antiproliferative and
differentiation-promoting effects of TGF-β do contributeto tumor suppression in human breast cancer. We had
previously shown that TGF-β can induce differentiation
in this breast cancer model [65], and here we demon-
strated that this effect is mediated by Smad3. However,
since the signature still prognosticated independently of
proliferation and tumor grade in multivariate analysis,
there are likely to be additional as yet unidentified bio-
logical activities that also contribute to the TGF-β-driven
tumor suppression. In terms of molecular mechanism, our
signature implicated Ephrin-A1 as a novel downstream
mediator contributing to TGF-β-driven tumor suppres-
sion. Like TGF-β signaling, ephrin signaling can have
pro-oncogenic or anti-oncogenic effects, depending on
the relative levels of ephrin ligands and receptors, and
the nature of the target cell [82-84]. In breast cancer
model systems, Ephrin-A1 signaling through the EphA2
receptor on the tumor cell can inhibit tumorigenesis
[89,90], whereas excess unliganded EphA2 promotes
tumorigenesis through enhanced proliferation and migra-
tion [90,91]. However, tumor-derived Ephrin-A1 ligand
can also have pro-oncogenic effects by promoting tumor
angiogenesis through the stimulation of EphA2 signaling
on endothelial cells [92]. Thus, as for TGF-β, a complex
balance of biological activities is at play. Our bioinformatic
data revealed a strong statistical relationship between
TGF-β tumor suppression and ephrin signaling in ER+
breast cancer datasets, and we demonstrated experimen-
tally that tumor-autonomous ephrin signaling suppresses
tumorigenesis in the M3 breast cancer model. Thus en-
hanced ephrin signaling plausibly contributes to tumor
suppression by TGF-β in ER+ breast cancer.Conclusions
We have generated a TGF-β/Smad3-driven gene expression
signature that specifically captures the tumor-suppressive
effects of TGF-β in ER+ breast cancer. High expression
of this signature was associated with good clinical out-
come in multiple ER+ breast cancer cohorts, suggesting
that tumor-suppressive effects of TGF-β are still active
and slowing disease progression at the time of surgery in a
significant fraction of breast cancer patients. Clearly such
patients should be excluded from treatment with thera-
peutic TGF-β antagonists. At a molecular level of reso-
lution, we found that cellular responses to TGF-β are even
more sensitive to contextual cues than was previously ap-
preciated, which suggests that distinct TGF-β signatures
may have to be generated for different tumor types or sub-
types. However, using integrated in vitro/in vivo strategies
such as ours, it is clearly possible to assess whether the
good or the bad sides of TGF-β dominate in determining
disease outcome. Such information will set the stage for
safer and more effective therapeutic exploitation of this
important signaling pathway in cancer.
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Additional file 1: Immunostaining for estrogen receptor in tumors
from M3 and M4 cells. Xenografted tumors from M3 and M4 cells were
immunostained for estrogen receptor alpha (ERα) as described in Methods.
Extensive ERα staining (brown nuclei) is apparent in well-differentiated
regions of the M3 tumors, but is also seen in regions of the more
poorly differentiated M4 tumors. H&E, hemotoxylin and eosin.
Additional file 2: Primer pairs for QPCR. All primers are in 5′ to 3′
orientation.
Additional file 3: Primer pairs for RT-QPCR. All primers are in 5′ to 3′
orientation.
Additional file 4: Location of Smad3 binding regions and their TGF-
β-induced occupancy by Smad3 in the four cell lines. Location of the
404 annotated SBRs and their occupancy in M1 to M4 cells was determined
from the ChIP-chip analysis. +, occupied; −, unoccupied. Genome coordinates
are Hg18.
Additional file 5: ChIP-QPCR validation of Smad3 target genes with
different occupancy patterns between the four cell lines. (A) A total
of 25 Smad3 target genes identified by TAS analysis of ChIP-chip data using
an FDR of 0.15 were validated by ChIP-QPCR across all four cell lines and
the pattern of gene occupancy was compared between the two methods.
The table gives the summary of the results. ChIP-QPCR peaks were scored
positive if TGF-β-induced occupancy was significant (P <0.05), and ≥2-fold
over untreated. A total of 65/67 of the Smad3 binding regions identified by
TAS from ChIP-chip in one or more of the cell lines were validated by QPCR.
However, QPCR was more sensitive and identified an additional 11/33
instances of Smad3 binding in genomic regions that were called negative
in one or more of the cell lines by TAS (see for example Smad3 occupancy
of LAMB3 promoter in M1 and M2). Thus the experimentally determined
FDR was 14%, with the majority (85%) of the false calls by ChIP-chip being
false negatives. IL31RA is included as an example of a gene that did not
show Smad3 occupancy in the ChIP-chip analysis. (B) Representative ChIP-
QPCR validation results are given for genes that show different patterns
of Smad3 promoter occupancy between the four cell lines by ChIP-chip.
Results are mean +/−SEM for three replicates. *Smad3 occupancy was
induced ≥2-fold by TGF-β and was statistically significant (P <0.05; unpaired
t test). IL31RA was selected as a gene that did not show Smad3 binding by
ChIP-chip. αS3, anti-Smad3 antibody; CON, control IgG.
Additional file 6: Petal plot showing patterns of TGF-β-regulated
gene expression in M1 to M4 cells. Global TGF-β-regulated gene
expression was determined by microarray analysis at the 6 hour time
point for all four cell lines. Using a fold-change cutoff of 1.5x and a
significance cutoff of P = 0.001, a total of 563 genes were found to be
significantly changed in their expression across the four cell lines. The
majority of these genes were unique to the individual cell lines.
Additional file 7: Expression of Smad3 occupied genes in vitro.
Considering only those genes that showed TGF-β-induced Smad3 occupancy,
the fraction of TGF-β/Smad3 target genes showing regulated mRNA
expression at 1 hour or 6 hours was determined from the microarray
analysis using a P value cutoff of <0.001 for differential expression
between the TGF-β-treated and untreated condition for a given cell line
and time point. SBR, Smad3 binding region.
Additional file 8: Immunostaining of M3 tumors for ANGPTL4 and
SERPINE1. M3 tumors were immunostained for ANGPTL4 and SERPINE1
as described in Methods. Immunostaining for both proteins was observed
predominantly in the tumor parenchyma (T) and not in the stroma (S).
Scale bar represents 25 μm.
Additional file 9: Smad3 target genes uniquely regulated by TGF-β
in M3 cells, and Smad3 target genes commonly regulated by TGF-β
in both M3 and M4 cells. From the gene expression microarray data, 38
TGF-β/Smad3 target genes were found to be uniquely regulated by TGF-
β in M3 and not in M4 cells in vitro (Tab A). A total of 65 TGF-β/Smad3
target genes were found to be regulated by TGF-β in both M3 and M4
cells in vitro (Tab B). The tables summarize the direction of regulation of
these genes by TGF-β in in vitro and in vivo. The direction of regulation
in vivo was determined by comparison of gene expression array datafrom M3 tumors with or without overexpression of a dnTβRII. The table
also indicates which of the genes that survived the in vivo filter were
represented in the GOBO clinical breast cancer array datasets. The 26
genes that were uniquely upregulated by TGF-β in M3 cells in vitro and
in vivo were validated by RT-QPCR of the tumors (Figure 5). Key: 1 =
upregulated by TGF-β; 0 = not regulated by TGF-β; −1 = downregulated
by TGF-β; NA, not applicable. For clarity, the final weighted TSTSS
signature is also given in Tab C. The table is given as an Excel Spreadsheet
with three tabs: Tab A, Tab B and Tab C.
Additional file 10: Prognostic power of the in vitro/in vivo concordant
and discordant genes sets from the TSTSS when analyzed separately.
Kaplan-Meier survival curves and multivariate analyses were generated
within the GOBO breast cancer datasets using (A) only genes whose
direction of regulation by TGF-β was concordant between in vitro and
in vivo; (B) only genes whose direction of regulation was discordant
in vitro and in vivo; and (C) the full TSTSS which includes both gene sets.
Of the 26 genes of the TSTSS, 20 were concordant and 6 were discordant.
A total of 16 of the 20 concordant genes were found in the GOBO datasets
(not found: ANXA2, C15orf57, FRMD6 and IRF2BP2). Four of the six discordant
genes were found in the GOBO datasets (not found: FMNL2 and TMEM88).
Additional file 11: Performance of a ‘generic’ TGF-β signature in
breast cancer cohorts using the GOBO meta-analysis tool. Kaplan-
Meier analyses were performed using the online GOBO tool to assess the
association of the TGF-β-regulated gene sets with distant metastasis-free
survival (DMFS) in a meta-analysis across the multiple breast cancer cohorts
of the GOBO dataset (1,379 tumors from eight cohorts). Patient datasets
representing all tumors were dichotomized to higher than median
expression (black) or lower than median expression (grey) of the gene
set. P values were determined by the log-rank test. This figure shows
Kaplan-Meier plots for survival of all patients in the GOBO datasets,
using a ‘generic’ TGF-β signature derived from the set of TGF-β/Smad3
target genes that were regulated in both M3 and M4 cells, and thus
not enriched for tumor-suppressor activity. Weighting (positive or
negative) of individual target genes is based on the directionality of
TGF-β-regulated expression of this gene set in M3 cells in vitro (A) or in
M3 tumors in vivo (B) as indicated. The list of genes involved is given in
Additional file 9. Note the greatly reduced statistical power of this signature
when compared to the use of the TSTSS tumor-suppressor signature in the
same cohorts (Figure 6A). Note also that high expression of the generic
TGF-β signature is associated with either good or bad outcome depending
on whether the in vitro or in vivo directional weighting was used, again
illustrating the strong influence that the biological context in which the
signature was generated has on its subsequent performance in the
clinical datasets.
Additional file 12: Performance of the TSTSS in independent
breast cancer cohorts. Kaplan-Meier analyses were performed using
the R Package ‘Survival’ to assess the association of the
TGF-β-regulated gene sets with distant metastasis-free survival (DMFS)
or overall survival (OS) in three independent breast cancer datasets
that were not included in the GOBO meta-analysis as they used
different gene expression array platforms. Patient datasets were
dichotomized to higher than median expression (black) or lower than
median expression (grey) of the gene set. P values were determined
by the log-rank test. Performance of the TSTSS (in vivo weighting) is
shown for ER+ breast cancer datasets from (A) the Nederlands Kanker
Instituut (NKI: n = 249), (B) the Cancer Genome Atlas (TCGA) cohort
(n = 407) and (C) the BT2000/Metabric (n = 1508) cohorts. (D) GSE6532
(Loi) is a component dataset from the GOBO cohorts using the
Affymetrix array platform that was reanalyzed using the same R
Package method for direct comparison.
Additional file 13: Correlation between the metaPCNA index or the
metaEphrin index and the TSTSS in additional ER+ breast cancer
cohorts. The metaPCNA index (A) is a surrogate for proliferation and the
metaEphrin index (B) is a surrogate for ephrin pathway activation in normal
cells. More details on the indices are given in Methods. The GSE6532 (Loi)
dataset contains 262 ER+ tumors, and the Nederlands Kanker Instituut (NKI)
dataset contains 249 ER+ tumors. The Spearman correlation coefficient is
given.
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Ingenuity Pathway Analysis was performed to identify networks formed by
the 26 genes of the TSTSS, and the top two networks are shown. Network 1
(score 32) is associated with the following network functions: Cardiovascular
System Development and Function, Embryonic Development and Function.
Network 2 (score 29) is associated with Cell Cycle, Digestive System
Development and Function, and Cancer. Red indicates TGF-β/Smad3
target genes that were upregulated by TGF-β in vivo, and green
indicates downregulated target genes. White shows non-target genes
that were used to generate the networks.
Additional file 15: Relative expression of the TSTSS in different
human breast cancer subtypes. Analyses were done using the GOBO
algorithm applied to all breast cancers in the GOBO database. (A) TSTSS
expression in breast cancers stratified by ER status. (B) TSTSS expression
in breast cancers stratified by intrinsic molecular subtype. HER2, HER2
amplified; Lum, luminal. The numbers of tumors in each category is given
at the top of the figure. ANOVA P values.
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